Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the presence of anti-GalNAc-GD1a antibodies in patients with Guillain-Barré syndrome (GBS) and to determine the relation of anti-ganglioside antibodies with clinical features. BACKGROUND: The GBS is heterogeneous with regard to clinical manifestations, antecedent infections, and the presence and specificity of anti-ganglioside antibodies. Recently, antibodies to minor gangliosides have been identified in serum from GBS patients. METHODS: The authors used ELISA to detect anti-ganglioside antibodies in 132 GBS patients and then correlated results with a database containing information on antecedent infections and clinical parameters. RESULTS: Anti-GalNAc-GD1a antibodies could be detected in 19 (14%) GBS patients. The presence of anti-GalNAc-GD1a antibodies was related to antecedent Campylobacter jejuni infection (p<0.001). GBS patients with anti-GalNAc-GD1a antibodies had a rapidly progressive, more severe, and predominantly distal weakness. Furthermore, they had less sensory loss, paresthesia, and cranial nerve involvement. In most patients, this reactivity was independent of reactivity to GM1. Dividing patients into separate groups based on their reactivity to GalNAc-GD1a and GM1 enabled the authors to delineate more homogeneous subgroups with regard to clinical features. CONCLUSIONS: This study provides further evidence for the hypothesis that antecedent infections and the specificity of subsequent anti-neural antibody responses determine the clinical manifestations in GBS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
van der Mech�, F. G. A., & van Doorn, P. A. (1995) · Annals of Neurology · doi:10.1002/ana.410370704 · Cited by 131
Cited by
Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00339-1 · Cited by 1,609
Self-citationClinical features, pathogenesis, and treatment of Guillain-Barré syndrome
van Doorn, P. A., Ruts, L., & Jacobs, B. C. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70215-1 · Cited by 828
Self-citationPeripheral neuropathies and anti-glycolipid antibodies
Willison, H. J. (2002) · Brain · doi:10.1093/brain/awf272 · Cited by 710
Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes
Yuki, N. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00019-6 · Cited by 326
Self-citationKolter, T. (2012) · ISRN Biochemistry · doi:10.5402/2012/506160 · Cited by 165
Metadata
- Authors
- Ang, C. W., Yuki, N., Jacobs, B. C., Koga, M., Van Doorn, P. A., Schmitz, P. I. M., & Van Der Meché, F. G. A.
- Venue
- Neurology
- Published
- 1999-12
- Volume
- 53
- Issue
- 9
- Pages
- 2122-2122
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2086806731
- Cited by
- 84
- References
- 1
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies. https://app.cochat.ai/papers/10.1212/wnl.53.9.2122
- The paper
- Ang, C. W., Yuki, N., Jacobs, B. C., Koga, M., Van Doorn, P. A., Schmitz, P. I. M., & Van Der Meché, F. G. A. (1999). Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies. Neurology. https://doi.org/10.1212/wnl.53.9.2122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.